モザバプタン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/10/08 05:51:53」(JST)
[Wiki en表示]
Mozavaptan
|
Systematic (IUPAC) name |
N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide |
Clinical data |
Pregnancy cat. |
? |
Legal status |
℞ Prescription only |
Routes |
Oral |
Identifiers |
CAS number |
137975-06-5 N |
ATC code |
None |
PubChem |
CID 119369 |
ChemSpider |
106618 Y |
UNII |
17OJ42922Y Y |
ChEMBL |
CHEMBL420762 Y |
Chemical data |
Formula |
C27H29N3O2 |
Mol. mass |
427.53 g/mol |
SMILES
- CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
|
InChI
-
InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) Y
Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N Y
|
N (what is this?) (verify)
|
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References[edit]
- H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
- Prous Science: Molecule of the Month November 2006
Antihypertensives: diuretics (C03)
|
|
Sulfonamides
(and etacrynic acid) |
CA inhibitors (at PT)
|
|
|
Loop (Na-K-Cl at AL)
|
- Furosemide#
- Bumetanide
- Etacrynic acid
- Etozoline
- Muzolimine
- Piretanide
- Tienilic acid
- Torasemide
|
|
Thiazides (Na-Cl at DCT,
Calcium-sparing)
|
- Hydrochlorothiazide#
- Bendroflumethiazide
- Hydroflumethiazide
- Chlorothiazide
- Polythiazide
- Trichlormethiazide
- Cyclopenthiazide
- Methyclothiazide
- Cyclothiazide
- Mebutizide
|
|
Thiazide-likes (primarily DCT)
|
- Quinethazone
- Clopamide
- Chlortalidone
- Mefruside
- Clofenamide
- Metolazone
- Meticrane
- Xipamide
- Indapamide
- Clorexolone
- Fenquizone
|
|
|
Potassium-sparing (at CD) |
ESC blockers
|
- Amiloride#
- Triamterene
- Benzamil
|
|
Aldosterone antagonists
|
- Spironolactone#
- Eplerenone
- Potassium canrenoate
- Canrenone
|
|
|
Osmotic diuretics (PT, DL) |
|
|
Vasopressin receptor antagonists
(DCT and CD) |
- vaptans: Conivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan
- tetracyclines: Demeclocycline
|
|
Other |
- mercurial diuretic (Mersalyl, Meralluride)
- Theobromine
- Cicletanine
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
anat (a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
|
noco/syva/cong/lyvd/tumr, sysi/epon, injr
|
proc, drug (C2s+n/3/4/5/7/8/9)
|
|
|
|
Neuropeptidergics
|
|
Cholecystokinin |
CCKA
|
- Agonists: Cholecystokinin
- CCK-4
Antagonists: Asperlicin
- Proglumide
- Lorglumide
- Devazepide
- Dexloxiglumide
|
|
CCKB
|
- Agonists: Cholecystokinin
- CCK-4
- Gastrin
Antagonists: Proglumide
- CI-988
|
|
|
CRH |
CRF1
|
- Agonists: Corticotropin releasing hormone
Antagonists: Antalarmin
- CP-154,526
- Pexacerfont
|
|
CRF2
|
- Agonists: Corticotropin releasing hormone
|
|
|
Galanin |
GAL1
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
GAL2
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
GAL3
|
- Agonists: Galanin
- Galmic
- Galnon
|
|
|
Ghrelin |
- Agonists: Ghrelin
- Capromorelin
- MK-677
- Sermorelin
- SM-130,686
- Tabimorelin
|
|
GnRH |
- Agonists: Buserelin
- Deslorelin
- GnRH
- Goserelin
- Histrelin
- Leuprorelin
- Nafarelin
- Triptorelin
Antagonists: Abarelix
- Cetrorelix
- Degarelix
- Ganirelix
|
|
MCH |
MCH1
|
- Agonists: Melanin concentrating hormone
Antagonists: ATC-0175
- GW-803,430
- NGD-4715
- SNAP-7941
- SNAP-94847
|
|
MCH2
|
- Agonists: Melanin concentrating hormone
|
|
|
Melanocortin |
MC1
|
- Agonists: alpha-MSH
- Afamelanotide
- BMS-470,539
- Bremelanotide
- Melanotan II
Antagonists: Agouti signalling peptide
|
|
MC2
|
- Agonists: ACTH
- Cosyntropin
- Tetracosactide
|
|
MC3
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
|
|
MC4
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
- PF-00446687
- THIQ
Antagonists: Agouti-related peptide
|
|
MC5
|
- Agonists: alpha-MSH
- Melanotan II
|
|
|
Neuropeptide S |
- Agonists: Neuropeptide S
Antagonists: SHA-68
|
|
Neuropeptide Y |
Y1
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIBP-3226
|
|
Y2
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIIE-0246
|
|
Y4
|
- Agonists: Neuropeptide Y
- Pancreatic polypeptide
- Peptide YY
Antagonists: UR-AK49
|
|
Y5
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: Lu AA-33810
|
|
|
Neurotensin |
NTS1
|
- Agonists: Neurotensin
- Neuromedin N
Antagonists: SR-48692
- SR-142,948
|
|
NTS2
|
- Agonists: Neurotensin
Antagonists: Levocabastine
- SR-142,948
|
|
|
Orexin |
OX1
|
- Agonists: Orexin-A
Antagonists: Almorexant
- SB-334,867
- SB-408,124
- SB-649,868
- Suvorexant
|
|
OX2
|
- Agonists: Orexin-A
Antagonists: Almorexant
- SB-649,868
- Suvorexant
- TCS-OX2-29
|
|
|
Oxytocin |
- Agonists: Carbetocin
- Demoxytocin
- Oxytocin
- WAY-267,464
Antagonists: Atosiban
- Epelsiban
- L-371,257
- L-368,899
- Retosiban
|
|
Tachykinin |
NK1
|
- Agonists: Substance P
Antagonists: Aprepitant
- Befetupitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- FK-888
- Fosaprepitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium
- Orvepitant
- RP-67,580
- SDZ NKT 343
- Vestipitant
- Vofopitant
|
|
NK2
|
- Agonists: Neurokinin A
Antagonists: GR-159,897
- Ibodutant
- Saredutant
|
|
NK3
|
- Agonists: Neurokinin B
Antagonists: Osanetant
- Talnetant
|
|
|
Vasopressin |
V1A
|
- Agonists: Desmopressin
- Felypressin
- Ornipressin
- Terlipressin
- Vasopressin
Antagonists: Conivaptan
- Demeclocycline
- Relcovaptan
|
|
V1B
|
- Agonists: Felypressin
- Ornipressin
- Terlipressin
- Vasopressin
Antagonists: Demeclocycline
- Nelivaptan
|
|
V2
|
- Agonists: Desmopressin
- Ornipressin
- Vasopressin
Antagonists: Conivaptan
- Demeclocycline
- Lixivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome.
- Ectopic ADH Syndrome Therapeutic Research Group, Yamaguchi K, Shijubo N, Kodama T, Mori K, Sugiura T, Kuriyama T, Kawahara M, Shinkai T, Iguchi H, Sakurai M.SourceOffice of the President, Shizuoka Cancer Center, Sunto-gun, Shizuoka 411-8777, Japan. k.yamaguchi@scchr.jp
- Japanese journal of clinical oncology.Jpn J Clin Oncol.2011 Jan;41(1):148-52. Epub 2010 Nov 17.
- Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard
- PMID 21087977
- [Vasopressin receptor antagonists: the vaptans].
- Villabona C.SourceServicio de Endocrinologia y Nutricion, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.Endocrinol Nutr.2010 May;57 Suppl 2:41-52.
- The non-peptide vasopressin antagonists (VPA), called vaptans, were developed in the 1990s to antagonize both the pressor and antidiuretic effects of vasopressin. There are three subtypes of VPA receptors: V1a, V1b and V2. V1a receptors are widely distributed in the body, mainly the blood vessels an
- PMID 21130961
Related Links
- Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ...
Related Pictures
![Copyright © DOB INTEGRATED CORPORATION](https://1mg.info/0/5/b/1366.jpg)
![Vaptans for the Treatment of Hyponatremia](https://1mg.info/0/5/b/1367.jpg)
![Mozavaptan structure.svg](https://1mg.info/0/5/b/1368.jpg)
![Figure CN101613317BD00041](https://1mg.info/0/5/b/1369.jpg)
![根据权利要求7的方法,其中所](https://1mg.info/0/5/b/1370.jpg)
★リンクテーブル★
[★]
- 英
- mozavaptan
- 化
- 塩酸モザバプタン、モザバプタン塩酸塩、mozavaptan hydrochloride
- 商
- フィズリン
- 関
- 利尿剤
バソプレシンV2受容体遮断薬;抗利尿ホルモン不適合分泌症候群治療
[★]
- 関
- mozavaptan